Search clinical trials for: Ad26.RSV.FA2 (JNJ-61187165-AAA)

Total 1198 results

Crucell Holland BV

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

Healthy Participants

United States
Crucell Holland BV

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

Respiratory Tract Infections | Respiratory Syncytial Viruses

United States
Bausch Health Americas, Inc.

Completed

A Study of a New Drug Treatment for Acne

Acne Vulgaris

United States
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris

Acne Vulgaris

Japan
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive (HORIZON 2)

Coronavirus Disease-2019 (COVID-19) Prevention

Mexico, South Africa, Brazil, Argentina, India
Janssen Vaccines & Prevention B.V.
Bavarian Nordic

Terminated

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Human Papillomavirus Infections

United States, Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

Healthy

United Kingdom
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 (Amplify)

Coronavirus Disease

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Adults (COVID-19)

Healthy

Netherlands
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

COVID-19 Prevention

United States, Germany, Brazil, Poland, South Africa
Janssen Pharmaceutical K.K.

Completed

A Study of Ad26.COV2.S in Adults (COVID-19)

Healthy

Japan
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

Healthy

United States
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants

Healthy Volunteers

Japan
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1)

COVID-19 Prevention

United States, South Africa, Brazil
Janssen Vaccines & Prevention B.V.

Completed

A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

Healthy

Belgium
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

Respiratory Tract Infections | Respiratory Syncytial Viruses

United Kingdom, Finland, United States
Janssen Research & Development, LLC

Completed

Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults

Healthy

United States
Janssen Research & Development, LLC

No longer available

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

Healthy
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Adults (COVID-19)

Covid-19 Prevention

Belgium, United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants (ENSEMBLE)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol

United States, Mexico, South Africa, Brazil, Chile, Colombia, Peru, Argentina
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents

Healthy

United Kingdom, Germany, Spain, Netherlands
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

Healthy

United States
Delta University for Science and Technology

Completed

Covid-19 Epidemic Lockdown Impact on Psychomotor Performance

Covid19 Epidemic Lockdown Impact

Egypt
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2)

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19

United States, United Kingdom, Belgium, Spain, France, Germany, Philippines, Brazil, Colombia, South Africa
Delta University for Science and Technology

Completed

Comparison Between Magnetic Field and Laser Therapy in Management of Trigeminal Neuralgia

Trigeminal Neuralgia

Egypt
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

COVID-19 Prevention

United States, Belgium, Poland
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

Healthy

United States
Delta University for Science and Technology

Completed

Correlation Between Body Weight and Foot Progression Angle in Adolescents

Obesity, Adolescent | Adolescent Development

Egypt
Delta University for Science and Technology

Completed

Muscle Energy Technique Versus Myofacial Release in Adolescents With Spinal Deformity

Idiopathic Spinal Deformities

Egypt
Delta University for Science and Technology

Completed

The Effect of Poorly Designed School Furniture on Children's Head and Scapulae Postures

Ergonomics

Egypt
The Aurum Institute NPC
Coalition for Epidemic Preparedness Innovations

Recruiting

Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults. (AUR1-8-341)

COVID-19

South Africa
Janssen Research & Development, LLC

Completed

Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants

Healthy

United States
University of Leicester

Unknown

NHS AAA Screening Programme Data Linkage With HES and ONS Datasets

AAA

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers

Healthy Volunteers
Medtronic Cardiovascular
The Cleveland Clinic

Terminated

The (PIVOTAL) Study

ABDOMINAL AORTIC ANEURYSMS

United States
Washington University School of Medicine

Recruiting

NIH CCR2 AAA Study

Abdominal Aortic Aneurysm (AAA) | No Abdominal Aortic Aneurysm (Non-AAA)

United States
Fondation Ophtalmologique Adolphe de Rothschild

Recruiting

Screening for Abdominal Aortic Aneurysms in the General Practice by Ultraportable Ultrasound (DACEP)

Abdominal Aortic Aneurysm

France
Imperial College London

Not yet recruiting

Sex-specific Differences in the Stress Response to Abdominal Aortic Aneurysm Repair (SSStressAAA)

Stress | Surgery | Abdominal Aortic Aneurysm

United Kingdom
Endologix

Active, not recruiting

Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices (LEOPARD)

Abdominal Aortic Aneurysm

United States
Göteborg University
Örebro University, Sweden; Karlstad Central Hospital

Recruiting

Myocardial Injury in Treatment of AAA (TREATROP)

Complication of Surgical Procedure | Aortic Aneurysm, Abdominal | Myocardium; Ischemic

Sweden
University of California, San Francisco

Recruiting

Follow-up After Endovascular Repair of Abdominal Aortic Aneurysm

Abdominal Aortic Aneurysm

United States
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France; APHP; Center... and other collaborators

Active, not recruiting

Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine (CoviComMali)

COVID-19 | Vaccine Adverse Reaction | Vaccine Reaction | SARS CoV 2 Infection

Mali
University of Washington

Recruiting

Physician Modified Endovascular Grafts (PMEG)

Abdominal Aortic Aneurysms

United States
Endologix

Recruiting

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization (JAGUAR)

AAA | AAA - Abdominal Aortic Aneurysm

United States
Janssen Korea, Ltd., Korea

Completed

A Study of the Newly Formulated Tylenol Tablet (Acetaminophen) to the Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants

Healthy

Korea, Republic of
Medtronic Cardiovascular

Completed

The Pivotal Study of the Aptus Endovascular AAA Repair System (STAPLE-2)

Abdominal Aortic Aneurysms (AAA)

United States
Boston Scientific Corporation

Withdrawn

The Boston Scientific ENOVUS Trial

Abdominal Aortic Aneurysm

3

Subscribe